ライフサイエンスコーパス: HIV antibody

1 nd intravenous immunoglobulin (IVIG) without HIV antibody.

2 mutants has not been delineated for an anti-HIV antibody.

3 llomavirus (HPV), Neisseria gonorrhoeae, and HIV antibody.

4 ion cassettes, or other broadly neutralising HIV antibodies.

5 n to be stable and to be recognized by known HIV antibodies.

6 sil, or spleen and only when armed with anti-HIV antibodies.

7 bind a variety of broadly neutralizing anti-HIV antibodies.

8 um samples that were repeatedly reactive for HIV antibodies.

9 n more potent than broadly neutralizing anti-HIV antibodies.

10 ty than well-known broadly neutralizing anti-HIV antibodies.

11 mens that had previously tested positive for HIV antibodies.

12 e enterotoxin (shortest distance 31 A), anti-HIV antibody 2G12 (shortest distance 31 A), concanavalin

13 recognized by the broadly neutralizing anti-HIV antibody 2G12 are 3-fold more abundant on the native

14 d by host antibodies such as the potent anti-HIV antibody 2G12 that binds high-mannose glycans on gp1

15 of ~10(13) that bind to broadly neutralizing HIV antibody 2G12 with 13 to 36 nM affinities.

16 hich were recognized by broadly neutralizing HIV antibody 2G12 with moderate affinities (150-500 nM K

17 proteins (Aspergillus niger phytase and anti-HIV antibody 2G12) produced in different plant species a

18 The broadly neutralizing anti-HIV antibody 4E10 recognizes an epitope very close to th

19 s) claim to detect both p24 antigen (Ag) and HIV antibodies (Ab) for early identification of acute in

20 An HIV antibody (Ab) against platelet integrin GPIIIa49-66

21 esting and blood screening algorithms detect HIV antibodies about 3 weeks after HIV infection.

22 tion, antigens (Ags) utilized to detect anti-HIV antibodies (Abs), and HIV subtype.

23 he presence of maternal or administered anti-HIV antibody, alternative strategies may be required to

24 after the exposure, no participant developed HIV antibodies, although a second PEP course for a subse

25 o determine the frequency of vaccine-induced HIV antibody among uninfected HIV vaccine trial particip

26 rth-generation immunoassays that detect both HIV antibodies and the p24 antigen, these are limited to

27 These distinctive activities suggest that HIV antibodies and their derivatives may play an importa

28 was to determine the timing of clearance of HIV antibodies and to identify any associated biological

29 Screening for HIV antibodies and viral RNA every 6 months has an ICER

30 yearly follow-up visits included testing for HIV antibody and assessment of behavioural outcomes.

31 e collected on dried blood spots to test for HIV antibodies, antiretroviral treatment (ART) exposure,

32 ot with HIV(IIIB), allowing for detection of HIV antibodies approximately 3 weeks earlier than by RT-

33 Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccin

34 Broadly neutralizing anti-HIV antibodies are rare and have proved hard to elicit w

35 Anti-HIV antibodies are therefore of great interest for vacci

36 Human immunodeficiency virus (HIV) antibodies are generated and maintained by ongoing

37 Sensitivity and specificity of a rapid HIV antibody assay based on comparisons with nonrapid as

38 the performance of a third-generation rapid HIV antibody assay tested at point-of-care (POC, Chembio

39 s of relatively inexpensive and quantitative HIV antibody assays may be useful indirect markers that

40 en percent of the infants had persistence of HIV antibodies at or beyond 18 months of age.

41 se the recognition of infected cells by anti-HIV antibodies at the cell surface, thereby reducing rec

42 tive for hepatitis B surface antigen or anti-HIV antibody at screening, or if they had previously bee

43 In conclusion, HIV antibody avidity testing provides a reliable method

44 vectors encoding a secretory monoclonal anti-HIV antibody, b12 (IgG(1)), we were able to program huma

45 in the United States and tested positive for HIV antibodies between 1988 and 1997 while living in the

46 Broadly neutralizing anti-HIV antibodies (bNAbs) binding to HIV envelope protein c

47 Broadly neutralizing HIV antibodies (bNAbs) can potently inhibit a wide range

48 Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-depend

49 of DNA coding for broadly neutralizing anti-HIV antibodies (bnAbs) offers an alternative to attempti

50 Apex broadly neutralizing HIV antibodies (bnAbs) recognize glycans and protein sur

51 t a targeted conjugate consisting of an anti-HIV antibody bound to a toxic moiety could function to k

52 In all, 4311 men were tested for HIV antibodies by enzyme-linked immunosorbent assay, wit

53 Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests tha

54 mbinations of polyclonal and monoclonal anti-HIV antibodies can produce additive or synergistic neutr

55 The therapies described here use anti-HIV antibodies conjugated to poisons to kill the cells i

56 es aimed at stabilizing this region in other HIV antibodies could become an important approach to in

57 , (iii) potentiates the non-membrane-binding HIV antibody D5 10-100-fold (depending on the virus stra

58 For visual or electronic reader HIV antibody detection, the sensitivity was 100% and the

59 mmunoassay for human immunodeficiency virus (HIV) antibody detection that localizes capture and detec

60 Higher levels of HIV antibodies during suppressive therapy were associate

61 Thus, comprehensively mapping HIV antibody escape gives a quantitative, mutation-level

62 Screening for HIV antibodies every 6 months costs $30,700/QALY gained.

63 eveloped to exploit the titer and avidity of HIV antibody evolution following seroconversion for inci

64 s encoding a mixture of broadly neutralizing HIV antibodies for the treatment of HIV infection, parti

65 mined for subjects who remained negative for HIV antibody for >or=3 months.

66 roup of related molecules, we cloned 576 new HIV antibodies from four unrelated individuals.

67 ogen design and as a bait for isolating anti-HIV antibodies from patient samples.

68 We have cloned anti-HIV antibodies from the memory B-cell compartment of six

69 A series of potent, broadly neutralizing HIV antibodies have been isolated from B cells of HIV-in

70 Recently, several neutralizing anti-HIV antibodies have been isolated from memory B cells of

71 Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were se

72 Clinical information and levels of HIV antibody, HIV RNA, and p24 antigen.

73 1 and promote the production of neutralizing HIV antibodies.IMPORTANCE There is a lack of understandi

74 Both assays detected HIV antibodies in men and women within 2 to 4 weeks of i

75 Clearance of HIV antibodies in uninfected infants was found to occur

76 we show that the polymeric IgA form of anti-HIV antibody inhibits HIV mucosal transmission more effe

77 Combining the detection of syphilis and HIV antibodies into one point-of-care test integrates sy

78 studies, the time to seroconversion for anti-HIV antibodies is 1-9 months (mean, approximately 2-3 mo

79 nistration-approved enzyme immunoassay (EIA) HIV antibody kits were used to determine VISP, and a rou

80 HIV antibody levels and HIV RNA viral loads were determi

81 Fourteen people with acute HIV infection (HIV antibody negative/NAT positive) were identified; the

82 x with men and transgender women with acute (HIV-antibody negative/HIV-1 RNA positive) or recent (con

83 3.3% of 1,656 treatment-naive, HIV antibody-negative individuals ultimately achieved SV

84 Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24

85 inics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable

86 V Combo] assay; Abbott Diagnostics) in 2,744 HIV antibody-negative samples.

87 NAAT identified 13 (0.1%) of the 12,338 HIV antibody-negative specimens as HIV RNA positive, wit

88 to HIV-infected mothers, 299 children became HIV-antibody-negative and 264 of these had been followed

89 gp160 enzyme immunoassay (EIA), detection of HIV antibodies occurred, on average, 33 days earlier tha

90 rospectively, a nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITEC

91 RNA positive) or recent (confirmed negative HIV-antibody or RNA test within 3 months) HIV infection,

92 with bNAbs only (VRC07-523LS and PGT128 anti-HIV antibodies) or a combination of bNAbs and Rh-a(4)B(7

93 ASI reported having sexual partners who were HIV antibody positive (odds ratio = 1.36, 95% confidence

94 d those who knew that the source subject was HIV antibody positive were more likely to recruit their

95 607/694 (87%) participants tested were HIV antibody positive.

96 Comprehensive HIV antibody profiles may prove useful for monitoring cu

97 HIV rapid tests (RTs) for anti-HIV antibodies provide results in less than 1 h and can

98 mune response to HIV often occurs-serum anti-HIV antibodies reactive with live HIV-infected cells, te

99 n induced a distinct and characteristic anti-HIV antibody response that, in some animals, included ne

100 d the extent of participation in the initial HIV antibody response, if any, are unclear.

101 influence the human immunodeficiency virus (HIV) antibody response produced during natural infection

102 We investigated whether HIV antibody responses as measured by high-throughput qu

103 vaccine might consider eliciting protective HIV antibody responses selectively from alternative B-ce

104 HIV antibody responses were measured over time in the pr

105 rategies to enhance systemic and mucosal SIV/HIV antibody responses.

106 We compared HIV antibody results between two of three treatment grou

107 e U.S. Food and Drug Administration-licensed HIV antibody screening, p24 antigen tests, HIV confirmat

108 t on a nucleic acid amplification test or as HIV antibody seroconversion.

109 ns with recent human immunodeficiency virus (HIV) antibody seroconversion is useful for treatment, re

110 pendently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which

111 found to encode broadly neutralizing mutated HIV antibodies, such as VRC01.

112 The rapid HIV antibody test demonstrated high sensitivity, specifi

113 rithm) as well as 1 algorithm that relies on HIV antibody testing alone (Antibody algorithm).

114 spective living organ donors, and to conduct HIV antibody testing and NAT as close to the time of don

115 us self-administered questionnaires and oral HIV antibody testing in MSM recruited in gay social venu

116 Physicians must perform HIV antibody testing to determine which persons are alre

117 Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fing

118 Peripheral blood samples were obtained for HIV antibody testing.

119 approximately 10% compared with conventional HIV antibody testing.

120 pared the diagnostic performance of standard HIV antibody tests (i.e., enzyme immunoassay and Western

121 HIV antibody tests cannot be used to reconfirm HIV diagn

122 man immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infe

123 (ED) use rapid human immunodeficiency virus (HIV) antibody tests as screening tools, despite limited

124 Rapid human immunodeficiency virus (HIV) antibody tests support the effort to expand access

125 Thus far, however, few broadly neutralizing HIV antibodies that occur naturally have been characteri

126 A fourth panel possessed early HIV antibodies that reacted with HIV(213) but not with H

127 with live HIV-infected cells, termed "early HIV antibodies." The specificities of these antibodies a

128 , however, are the unique properties of anti-HIV antibodies: the potential ability to opsonize viral

129 Anti-HIV antibody titers did not differ between study arms.

130 We have attached poisons to anti-HIV antibodies to kill the infected cells that persist e

131 nability of most known specificities of anti-HIV antibodies to neutralise HIV primary isolates consis

132 ministered a macaque version of a human anti-HIV antibody to monkeys, after which the antibody persis

133 The detection of HIV antibodies was achieved with an electrochemical immu

134 based on combinations of results of HIV RNA, HIV antibody, Western blot or Geenius assay, and/or the

135 s in the development of multifunctional anti-HIV antibodies, which may be important to prevent HIV-1

136 tion, the addition of one-time screening for HIV antibodies with an enzyme-linked immunosorbent assay

137 ed the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat

138 which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, mak